ULTOMIRIS® is available as 300 mg/3 mL and 1,100 mg/11 mL concentrates for solution for infusion. This calculator is intended for use when administering doses of ULTOMIRIS® 100 mg/mL only.** For dosing information regarding ULTOMIRIS® 10 mg/mL (300 mg/30 mL), please see the full Summary of Product Characteristics.1
In the absence of compatibility studies, ULTOMIRIS® 300 mg/30 mL concentrate for solution for infusion must not be mixed with ULTOMIRIS® 300 mg/3 mL or 1,100 mg/11 mL concentrates for solution for infusion.1
Drag the button across the slider bar in order to select your patient's body weight (kg). The body weight variable will automatically snap to the nearest recognised figure in line with the ULTOMIRIS® weight-based dosing.
*This dosing calculator is intended for use by healthcare professionals only. All calculations must be confirmed before use. The information provided does not replace clinical judgment. Please also refer to the Summary of Product Characteristics before prescribing and administration.
With ULTOMIRIS® 100 mg/mL, there is an optimal vial mix (3 mL and 11 mL) for each patient weight cohort, ensuring there is no product wastage.1
Adverse Event Reporting
Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com/
**ULTOMIRIS® must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological, renal, neuromuscular or neuroinflammatory disorders.1
† SOLIRIS® (eculizumab) is indicated in adults and children for the treatment of Atypical haemolytic uremic syndrome (aHUS).2
‡ ULTOMIRIS® should only be diluted using sodium chloride 9 mg/mL (0.9 %) solution for injection.1
§ Patients must be vaccinated against meningococcal infection 2 weeks prior to initiating treatment. If patients need to initiate ravulizumab treatment less than 2 weeks after receiving a meningococcal vaccine, must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination.1
healthcare professional